Aurobindo PharmaBOM:524804 -0.39%85 Net Margin % is 10.53% as of Mar. 2026, which is 11% below its 10-year median of 11.82. GuruFocus rates BOM:524804 with a GF Score™ of 85/100 and a GF Value™ of ₹1,322.24 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 953 Drug Manufacturers companies, Aurobindo Pharma ranks better than 65.69% on this metric.
The historical rank and industry rank for Aurobindo Pharma's Net Margin % or its related term are showing as below:
BOM:524804'
s Net Margin % Range Over the Past 10 Years
Min: 7.83 Med: 11.82 Max: 21.72
Current: 10.5
BOM:524804's Net Margin % is ranked better than 65.69% of 953
companies
in the Drug Manufacturers industry
Industry Median: 5.69
vs BOM:524804: 10.50
Aurobindo Pharma (BOM:524804) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Aurobindo Pharma Net Margin % Related Terms
Aurobindo Pharma Net Margin % Historical Data
* Premium members only.
The historical data trend for Aurobindo Pharma's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Aurobindo Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurobindo Pharma Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aurobindo Pharma's Net Margin % distribution charts can be found below:
* The bar in red indicates where Aurobindo Pharma's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurobindo Pharma (BOM:524804) has a Net Margin % of 10.53% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Aurobindo Pharma and its competitors. This is 11% below median its historical median of 11.82. Over the past decade, Aurobindo Pharma's Net Margin % has ranged from 7.83 to 21.72. According to the industry distribution chart, Aurobindo Pharma ranks #327 out of 953 companies in the Drug Manufacturers industry, placing it in the top 34.3%.
Is Aurobindo Pharma's Net Margin % too high?
Aurobindo Pharma's current Net Margin % of 10.53% is 11% below median its 10-year median of 11.82. Over the past 10 years, this metric has ranged from a low of 7.83 to a high of 21.72. The Drug Manufacturers industry median Net Margin % is 5.69. Aurobindo Pharma's value of 10.53% is 85.1% above this industry median. Based on the distribution chart, Aurobindo Pharma ranks #327 out of 953 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Aurobindo Pharma has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aurobindo Pharma's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aurobindo Pharma ranks #327 out of 953 companies for Net Margin %. This puts Aurobindo Pharma in the upper half of its industry. The industry median Net Margin % is 5.69. Aurobindo Pharma's value of 10.53% is 85.1% above this benchmark. Historically, Aurobindo Pharma's own Net Margin % has ranged from 7.83 to 21.72 over the past decade. While the company's 10-year median is 11.82 vs. the industry median of 5.69, Aurobindo Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.69, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aurobindo Pharma's current Net Margin % of 10.53% is 85.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Aurobindo Pharma and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurobindo Pharma's current Net Margin % is 10.53%, which is 11% below median its own 10-year median of 11.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurobindo Pharma stock overvalued right now?
Based on GuruFocus' analysis, Aurobindo Pharma (BOM:524804) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,322.24, compared to a current price of ₹1,548.85 — trading 17.1% above its estimated fair value. The current Net Margin % is 10.53%, which is 11% below median its 10-year median of 11.82 and 85.1% above the Drug Manufacturers industry median of 5.69. Aurobindo Pharma's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Aurobindo Pharma (BOM:524804), the current Net Margin % is 10.53% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurobindo Pharma (BOM:524804) Overvalued in 2026?
Based on GuruFocus' analysis, Aurobindo Pharma stock appears to be overvalued.
The current stock price of ₹1,548.85 is trading 17.1% above its estimated GF Value™ of ₹1,322.24.
GuruFocus considers Aurobindo Pharma to be Modestly Overvalued.
Key valuation signals for BOM:524804:
Net Margin %: 10.53% (11% below median its 10-year median of 11.82)
GF Value™: ₹1,322.24 vs. price of ₹1,548.85 (17.1% above fair value)
Industry Position: 85.1% above the Drug Manufacturers median (#327 of 953)
No single metric tells the full story. See the BOM:524804 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. It is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Its formulations target key therapeutic areas, including Central Nervous System (CNS), Antibiotics, Anti-diabetics, Cardiovascular, Anti-retroviral, Gastroenterology, Oncology, and Dermatology. The operating and reportable segments of the company are; India, the United States of America, Europe, and the Rest of the World. The company generates a majority of its revenue from its business in the United States of America.
85GF Score
Get the complete analysis for BOM:524804
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524804 has been successfully added to your 
